All news

Tonix Pharmaceuticals Holding Releases Q3 2026 Financial Results

Alpha Vantage · AlphaStreet · · AI-summarised by FinFlash

Tonix Pharmaceuticals Holding Corp. (TNXP) reported its Q3 2026 financial results, with a diluted loss of $2.89 per share, wider than analysts' expectations. However, the company's revenue of

Read original source

TNXP company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.